Healthcare
SpineGuard and Omnia Medical Obtain a New U.S. Patent for Their Innovative Application of DSG Technology to Sacroiliac Joint Fusion
PARIS & BOULDER, Colo., July 27, 2026--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company specializing in Dynamic Surgical Guidance (DSG®) technology to enhance the safety and efficiency of bone implant placement, and Omnia Medical, an orthopedic implant company focused on innovative spine and sacroiliac solutions, today announced that their U.S. patent application has received notice of allowance from the USPTO (United States Patent and Trademark Office) for their innovat
About this update from Spineguard
PARIS & BOULDER, Colo., July 27, 2026--(BUSINESS WIRE)--Regulatory News: SpineGuard (FR0011464452 - ALSGD), an innovative company specializing in Dynamic Surgical Guidance (DSG®) technology to enhance the safety and efficiency of bone implant placement, and Omnia Medical, an orthopedic implant company focused on innovative spine and sacroiliac solutions, today announced that their U.S. patent application has received notice of allowance from the USPTO (United States Patent and Trademark Office) for their innovative application of DSG technology to sacroiliac joint fusion. The recently allowed patent applications by the USPTO, applied jointly by SpineGuard and Omnia Medical, describes the utilization of the DSG tissue differentiating feedback technology to the precise positioning of sacroiliac fusion implants. It is the fruit of a co-development effort to offer to the U.S. market a reliable, while simple and efficient procedural solution for successful treatment of sacroiliac joint degeneration and pain. The sterile-delivered surgical kit that includes Omnia's implants, instruments, biologics, as well as SpineGuard's PsiFGuard guidance tool, is particularly well suited for light operative setups such as ambulatory centers or offices. The commercial launch acceleration of the product combination in the U.S., with its now fully protected surgical technique, is a key step of the common roadmap announced by both companies early 2025. Stéphane Bette, Deputy CEO and cofounder of SpineGuard, stated: "The SpineGuard team is proud to collaborate with Omnia Medical to offer the best solution to patients and physicians in an already large and fast-growing market segment: the posterior sacroiliac joint fusion in the USA. This represents for our DSG technology a very promising application that should contribute more and more to increasing our top line and reaching our operational profitability goal." Troy Schifano, CEO and Co-Founder of Omnia Medical, added: "This patent allowance further strengthens Omnia Medical's leadership in posterior sacroiliac fusion and reflects the power of our collaboration with SpineGuard. Together, we've developed the only enabling technology specifically designed to identify the sacroiliac joint during posterior SI fusion procedures. Innovation is what defines Omnia, and we will continue to protect the technologies we create in a marke...